$13.9MSeries C, 6 June 2025
Series C1 to accelerate clinical trials, including Claudin18.2 bispecific Q-1802 in gastric cancer.
- Amount
- $13.9M
- Stage
- Series C
- Announced
- 6 June 2025
- Lead
- Efung Capital
- Use of funds
- Series C1 to accelerate clinical trials, including Claudin18.2 bispecific Q-1802 in gastric cancer.
- Checked
- Amount and date matched across 2 press sources
- Sources
- QureBio raises CNY 100M (~$14M) Series C1 biospectrumasia.com
QureBio raises CNY 100M (~$14M) Series C1 techstartups.com